Previous 10 | Next 10 |
– Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress – – Discussions with regulatory agencies regarding Phase 3 NASH program...
SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic di...
2023-06-27 13:03:37 ET Biopharmaceutical firms focused on liver diseases trended lower Tuesday after pharma giant Eli Lilly ( NYSE: LLY ) announced data highlighting the potential of its weight loss candidate retatrutide in obese patients with excess liver fat. The condition kno...
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – SAN FRANCI...
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in significant benefit across several ...
2023-06-12 15:19:02 ET Summary Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need. The company's lead product candidate has shown promising and highly significant results in Phase 2b trials for NASH, primary and seco...
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic di...
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonal...
2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...
2023-05-28 04:18:19 ET Summary ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now. The data is very competitive. I have been covering 89bio ( ETNB ) for a few years now. I also added it to the List, but it was not a good idea in 2021....
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...